CD34 and breast cancer: Carter and colleagues [40] have analyzed the expression of p53 and MDM2 in BC-CML cells and in proliferating and quiescent CD34+ CML progenitor cells, demonstrating a heterogeneous expression in cells from BC-CML patient samples.